Advanced Therapies Journal

Advanced Therapies Journal

Niosome-Based Nanotechnology in Breast Cancer Therapy: Advances in Targeted Drug Delivery

Reviewers

Author
Seyede Fatemeh Tabatabaii
Department of Biological Sciences, Faculty of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran.
10.22034/atj.2026.252817
Abstract
Breast cancer remains a leading health concern among women worldwide, owing to its high incidence and substantial impact on morbidity and healthcare systems. Despite significant advances in diagnostic and therapeutic approaches, tumor molecular heterogeneity, drug resistance, disease recurrence, and treatment-associated systemic adverse effects remain major obstacles to achieving effective and safe therapy. In recent years, nanotechnology has provided promising opportunities for improving cancer treatment. Among various nanocarriers, niosomes have attracted considerable attention because of their favorable stability, surface modification potential, and controlled drug-release properties. This review examines the structure and composition of niosomes, their preparation and optimization methods, and their applications in the delivery of anticancer drugs. Furthermore, the role of modified and targeted niosomes in enhancing drug accumulation and penetration into tumor tissue while reducing systemic toxicity is discussed. In addition to conventional chemotherapeutic agents, the potential of niosomes for delivering novel anticancer therapeutics, including DNA, siRNA, miRNA, and other biological agents, is also addressed. Available evidence suggests that targeted niosomes can improve therapeutic efficacy by enhancing cellular uptake and controlling drug release while reducing drug exposure in healthy tissues. However, challenges including formulation instability, precise control of physicochemical properties, potential toxicity, manufacturing scalability, and limited clinical evidence remain. The development of smart, multifunctional, and personalized niosomal systems may shape the future of this technology in precision breast cancer therapy.
Keywords
Nanobiotechnology
Niosomes
Nanodrug Delivery
Targeted Delivery
Cancer Therapy
1.Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10:49. doi:10.1038/s41392-024-02108-4.
2.Cobb AN, Czaja R, Jorns J. Breast cancer subtypes: clinicopathologic features and treatment considerations. Curr Breast Cancer Rep. 2024;16(2):150-160. doi:10.1007/s12609-024-00541-6.
3.Li X, et al. Current understandings and clinical translation of nanomedicines for breast cancer therapy. Adv Drug Deliv Rev. 2022;180:114034. doi:10.1016/j.addr.2021.114034.
4.Corral A, et al. Actively targeted nanomedicines in breast cancer: from pre-clinical investigation to clinic. Cancers (Basel). 2022;14(5):1198. doi:10.3390/cancers14051198.
5.Liga S, Paul C, Moacă EA, Péter F. Niosomes: composition, formulation techniques, and recent progress as delivery systems in cancer therapy. Pharmaceutics. 2024;16(2):223. doi:10.3390/pharmaceutics16020223.
6.Roostaee M, Derakhshani A, Mirhosseini H, Banaee Mofakham E, Fathi-Karkan S, Mirinejad S, et al. Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer. Nanoscale. 2024;16(6):2713-2746. doi:10.1039/D3NR03495J.
7.Mawazi SM, Ge Y, Widodo RT. Niosome preparation techniques and structure—an illustrated review. Pharmaceutics. 2025;17(1):67. doi:10.3390/pharmaceutics17010067.
8.Liga S, Paul C, Moacă EA, Péter F. Niosomes: composition, formulation techniques, and recent progress as delivery systems in cancer therapy. Pharmaceutics. 2024;16(2):223. doi:10.3390/pharmaceutics16020223.
9.Roostaee M, Derakhshani A, Mirhosseini H, Banaee Mofakham E, Fathi-Karkan S, Mirinejad S, et al. Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer. Nanoscale. 2024;16(6):2713-2746. doi:10.1039/D3NR03495J.
10.Liga S, Paul C, Moacă EA, Péter F. Niosomes: composition, formulation techniques, and recent progress as delivery systems in cancer therapy. Pharmaceutics. 2024;16(2):223. doi:10.3390/pharmaceutics16020223.
11.Atyabi F, et al. Folic acid-decorated pH-responsive nanoniosomes with enhanced endocytosis for breast cancer therapy: in vitro studies. J Drug Deliv Sci Technol. 2022;71:103267. doi:10.1016/j.jddst.2022.103267.
12.Saharkhiz S, Nasri N, Naderi N, et al. Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells. Int J Pharm X. 2024;7:100237. doi:10.1016/j.ijpx.2024.100237.
13.Zenjanab MK, Dalir Abdolahinia E, et al. Hyaluronic acid-targeted niosomes for effective breast cancer chemostarvation therapy. ACS Omega. 2024;9(9):10875-10885. doi:10.1021/acsomega.3c09782.
14.Malathi S, Sisila V, Singaravel V, Venkatesan N, Pakrudheen I, Dhanaraj R, et al. Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy. Mater Adv. 2023;4:5224-5237. doi:10.1039/D3MA00328K.
15.Malathi S, Sisila V, Singaravel V, Venkatesan N, Pakrudheen I, Dhanaraj R, et al. Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy. Mater Adv. 2023;4:5224-5237. doi:10.1039/D3MA00328K.
16.Liga S, Paul C, Moacă EA, Péter F. Niosomes: composition, formulation techniques, and recent progress as delivery systems in cancer therapy. Pharmaceutics. 2024;16(2):223. doi:10.3390/pharmaceutics16020223.
17.Gupta R, Jasim HF, Al-Khafaji ZA, Ballal S, Nayak PP, Sharma R, et al. Updates on niosomes in interfering nucleic acid delivery for cancer treatment: a comprehensive review and future perspectives. Med Oncol. 2026;43(3):130. doi:10.1007/s12032-025-03221-2.
18.Roostaee M, Derakhshani A, Mirhosseini H, Banaee Mofakham E, Fathi-Karkan S, Mirinejad S, et al. Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer. Nanoscale. 2024;16(6):2713-2746. doi:10.1039/D3NR03495J.
19.Roostaee M, Derakhshani A, Mirhosseini H, Banaee Mofakham E, Fathi-Karkan S, Mirinejad S, et al. Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer. Nanoscale. 2024;16(6):2713-2746. doi:10.1039/D3NR03495J.
20.Gupta R, Jasim HF, Al-Khafaji ZA, Ballal S, Nayak PP, Sharma R, et al. Updates on niosomes in interfering nucleic acid delivery for cancer treatment: a comprehensive review and future perspectives. Med Oncol. 2026;43(3):130. doi:10.1007/s12032-025-03221-2.
21.Sahrayi H, Hosseini E, Karimifard S, Khayam N, Meybodi SM, Amiri S, et al. Co-delivery of letrozole and cyclophosphamide via folic acid-decorated nanoniosomes for breast cancer therapy: synergic effect, augmentation of cytotoxicity, and apoptosis gene expression. Pharmaceuticals (Basel). 2022;15(1):6. doi:10.3390/ph15010006.
22.Akbarzadeh I, Shayan M, Bourbour M, et al. Preparation, optimization and in-vitro evaluation of curcumin-loaded niosome@calcium alginate nanocarrier as a new approach for breast cancer treatment. Biology (Basel). 2021;10(3):173. doi:10.3390/biology10030173.
23.Saharkhiz S, Zarepour A, Nasri N, Cordani M, Zarrabi A. A comparison study between doxorubicin and curcumin co-administration and co-loading in a smart niosomal formulation for MCF-7 breast cancer therapy. Eur J Pharm Sci. 2023;191:106600. doi:10.1016/j.ejps.2023.106600.
24.Malathi S, Sisila V, Singaravel V, Venkatesan N, Pakrudheen I, Dhanaraj R, et al. Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy. Mater Adv. 2023;4:5224-5237. doi:10.1039/D3MA00328K.
25. Faddah H, Nsairat H, Shalan NM, El-Tanani M, Alqudah DA, Alshaer W. Preparation, optimization and in vitro evaluation of doxorubicin-loaded into hyaluronic acid coated niosomes against breast cancer. Chem Biodivers. 2024;21(2):e202301470. doi:10.1002/cbdv.202301470.
26.Ekhteraei‐Tousi S, Mohammad‐Soltani B, Sadeghizadeh M, Mowla SJ, Parsi S, Soleimani M. Inhibitory effect of hsa‐miR‐590‐5p on cardiosphere‐derived stem cells differentiation through downregulation of TGFB signaling. Journal of cellular biochemistry. 2015 Jan;116(1):179-91.
27.Tajer-Mohammad-Ghazvini P, Kasra-Kermanshahi R, Nozad-Golikand A, Sadeghizadeh M, Ghorbanzadeh-Mashkani S, Dabbagh R. Cobalt separation by Alphaproteobacterium MTB-KTN90: magnetotactic bacteria in bioremediation. Bioprocess and biosystems engineering. 2016 Dec;39(12):1899-911.
28.Noormohammadi Z, Hosseini-Mazinani M, Trujillo I, Rallo L, Belaj A, Sadeghizadeh M. Identification and classification of main Iranian olive cultivars using microsatellite markers. Hortscience. 2007 Dec 1;42(7):1545-50.
29.Arzi L, Riazi G, Sadeghizadeh M, Hoshyar R, Jafarzadeh N. A comparative study on anti-invasion, antimigration, and antiadhesion effects of the bioactive carotenoids of saffron on 4T1 breast cancer cells through their effects on Wnt/β-catenin pathway genes. DNA and cell biology. 2018 Aug;37(8):697-707.
30.Safari S, Malekvandfard F, Babashah S, Alizadehasl A, Sadeghizadeh M, Motavaf M. Mesenchymal stem cell-derived exosomes: A novel potential therapeutic avenue for cardiac regeneration. Cellular and Molecular Biology. 2016 Jun 30;62(7):66-73.

  • Receive Date 12 June 2026
  • Revise Date 16 July 2026
  • Accept Date 23 August 2026